18 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
and elicited tumor-specific in situ production of oncolytic virions, broad immune cell recruitment and tumor destruction. Efficacy was observed across multiple
8-K
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
in tumor-specific in situ production of oncolytic virions, broad immune cell recruitment and tumor destruction. Efficacy was observed across multiple
10-K
bmepy
10 Mar 21
Annual report
4:12pm
424B4
vl5z84prna d8cyr
12 Feb 21
Prospectus supplement with pricing info
4:23pm
DRS
r2gl5niv925u m8t
28 Jan 21
Draft registration statement
12:00am
10-Q
nan8bpm1k7la
12 Nov 20
Quarterly report
8:01am
424B4
klwtoo0
2 Oct 20
Prospectus supplement with pricing info
12:00am
S-1
zgq 74lxt6a
11 Sep 20
IPO registration
4:49pm
DRS/A
h9lhfwyr
26 Aug 20
Draft registration statement (amended)
12:00am
DRS/A
kqo6sf7
29 Jul 20
Draft registration statement (amended)
12:00am
DRS/A
tf1bqwh uzismpd2xurc
20 Dec 19
Draft registration statement (amended)
12:00am
DRS
kwlw89v7dz4eu
31 Oct 19
Draft registration statement
12:00am
- Prev
- 1
- Next